Johnson & Johnson Seeks EMA Approval for Ibrutinib Plus R-CHOP in Frontline MCL
Johnson & Johnson has submitted a type II variation application to the EMA seeking the approval of ibrutinib plus R-CHOP in ASCT-eligible frontline MCL.
Related Articles
Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA)
The advocacy Women Against Lung Cancer in Europe (WALCE) promoted the European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA) and…
Victoria’s Secret Global Fund for Women’s Cancers Rising Innovator Research Grants, in Partnership with Pelotonia & AACR
$700,000 over three years for female associate professors performing research that has a direct applicability and relevance to the understanding, prevention, interception, early detection, diagnosis,…
Belzutifan Plus Cabozantinib: A First-Line Treatment for Advanced RCC?
“The results of this first phase 2 study of belzutifan combined with cabozantinib suggest that dual targeting of HIF-2α and VEGF pathways might be an…
Fructose takes a detour to feed cancer
Nature Reviews Cancer – The mechanisms by which dietary fructose promotes tumour progression have remained poorly understood. A recent study published in Nature reveals that…
Multidisciplinary Collaboration Is Crucial in Managing Ocular Toxicities of Mirvetuximab Soravtansine in Gynecologic Tumors
Rebecca Arend, MD, and Kathryn Lyle, CRNP, discuss their approach to managing ocular and other treatment-related toxicities associated with mirvetuximab soravtansine.
OCE Conversations on Cancer – Cervical Cancer Treatment Innovation: A Collaborative Discussion
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Recent Advances in Fabry Disease Clinical Research
David Warnock, MD, Professor of Medicine (Emeritus), University of Alabama at Birmingham, discusses recent advances in Fabry disease.
Behind the TRIANGLE Study in MCL With Dr. Dreyling
Martin Dreyling, MD, discusses the final follow-up results of the TRIANGLE study in mantle cell lymphoma.
SBRT/Concurrent Chemoradiotherapy Shows Favorable Activity in NSCLC
Although not hitting its primary end point, a phase 2 trial showed that SBRT plus concurrent radiotherapy improved on results elicited in other trials.
Upcoming FDA-AACR Workshop Will Discuss DPD Deficiency Testing
A FDA-AACR workshop will discuss the considerations for DPD deficiency testing before chemotherapy with fluoropyrimidines.